Hope everyone has had a brilliant Christmas and New Year? Just a quickie for the new year – very proud to let you know that beczema.com was listed as one of 2017’s top health blogs by Home Remedies for Life If you’re new to beczema and are suffering with your …
beczema
Tag Archives: 2017
What Word Best Describes 2017?
The success of the Stoptober 2017 campaign
For another year, a focus on quitting smoking swept the nation with the Stoptober campaign. This is a 28 day long event run each October during which smokers are inspired to stop smoking.
There is always a considerable amount of buzz on the run up to Stoptober, encouraging and supporting smokers across the UK to sign up. Stoptober events include focusing on celebrities who are taking part to rouse the UK to stand together to quit smoking and enjoy the numerous benefits of a smoke-free lifestyle.
Coronation Street actress Kym Marsh supported this year’s campaign as she has not only given up smoking, but she also encouraged her teenage daughter to swap smoking for vaping as well. Vaping uses an e-cigarette to allow you to inhale nicotine through vapour rather than smoke. E-cigarettes are a great way to help buck nicotine cravings at the fraction of the health risk of cigarettes.
The idea behind Stoptober is based the evidence that after twenty eight days without a cigarette, smokers are as much as five times more likely to give up smoking permanently.
It is easy to see why Stoptober offers such a winning formula. Giving up smoking can be a huge challenge, but there is an immense amount of support available during and after the campaign from sources including:
- The NHS
- Friends and family
- The Stoptober mobile app
- Stoptober emails
- Social media group encouragement
- The collective boost of other participants
This year’s campaign highlighted that vaping is now the most popular method of stopping smoking, with 53%of people using e-cigarettes to try and quit smoking.
For the first time, vaping officially featured within the NHS Stoptober campaign, including the Stoptober TV advertisement.
Following this advocacy from the NHS, Vape Club reported that they have seen e-cigarette starter kit sales increase by 37% year on year.
Director of Vape Club Dan Marchant says that this medical acceptance has provided a pivotal moment for public health in relation to vaping:
‘It’s fantastic to see the NHS finally backing vaping as a pathway to quit smoking.
The industry has been backing this alternative for a long time, but with the evidence provided by Public Health England, endorsements from the likes of Cancer Research UK and the figures which are produced by Action on Smoking and Health (ASH), there can be no doubt that vaping is the most effective method to give up tobacco.
The NHS advocating vaping as an alternative to tobacco is an enormous breakthrough and will do an outstanding amount of good for public health and tobacco control in the UK.’
E-cigarettes are believed to be 95% less harmful than traditional tobacco and are officially included within the NHS’ Stoptober campaign as a way of gently phasing out tobacco. This is deemed much more realistic as opposed to the ‘cold turkey’ approach.
Through the adoption of this harm reduction strategy, the UK is fast becoming the European leader with success rates for quitting smoking at an all time high.
E-cigarettes are particularly powerful when combined with support from stop smoking services. People who choose to vape have some of the highest quitting success rates. E-cigarettes aren’t currently available on NHS prescription, but they can be bought in shops and online.
The yearly success of the Stoptober campaign is morale boosting. However, you don’t need a campaign to stop smoking. If you would like to quit you can set your own timeline, for example by trying to stop smoking before Christmas or the New Year. The key is that an event boosts your willpower – finding a reason to give up will always be advantageous.
Content supplied by Holly Barry at Distinctly PR
New products for November 2017
Aarkstore Enterprise – Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017
Aarkstore announce a new report “Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017 ” through its vast collection of market research report.
Summary
“Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Atopic Dermatitis therapeutics market. The report identifies the key trends shaping and driving the global Atopic Dermatitis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Atopic Dermatitis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global atopic dermatitis therapeutics market to be valued at $ 728m in 2009. It is expected to grow to $ 942m at a Compound Annual Growth Rate (CAGR) of 3.3% by 2017. This growth is primarily attributed to an increase in competition among existing products and the presence of a strong pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $ 415m in 2009.However, with most of the demand expected to come from the developed economies, the center of global atopic dermatitis therapeutics market activity is potentially due for a paradigm shift.
Scope
The scope of the report includes:
– Annualized global Atopic Dermatitis therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
– Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
– Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Anti-inflammatory, Corticosteroid, Interleukin Inhibitor, Antimicrobial, Immunomodulators, Protease Inhibitor, Nuclear Factor-Kappa B (NF-kB) inhibitor, Selective cannabinoid 2 receptor agonist, T-cell inhibitor, Vitamin D derivative, Cytokine Modulator, NO synthase inhibitor, Kinase Inhibitor,Calcineurin Inhibitor, Anti-pruritic, Histamine H1 antagonist, Chymase inhibitor, Anti-Neoplastic, TNF Antagonist, Non-steroid, Anti-itching, Vaccine, Combination, H4R antagonist, Serine proteinase inhibitor, RAFT modulator, Neurokinin 1 (NK1) receptor agonists, Vascular adhesion protein-1 (VAP-1) inhibitor, non-comedogenic, Fibroblast Growth Factor (FGF) inhibitor, TSLP interaction Inhibitor, Phosphodiesterase 4 (PDE4) Inhibitor, NGF receptor blocker and Glucocorticoid receptor agonist.
– Analysis of the current and future market competition in the global Atopic Dermatitis therapeutics market. The key future market players covered are Provectus Pharmaceuticals, AnGes MG Inc., Creabilis Therapeutics, Asubio Pharma, Almirall, Anacor Pharma, MIKA Pharma GmbH, Shionogi USA, Inc. and Serentis Ltd
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
– Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Atopic Dermatitis market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
– Develop business strategies by understanding the trends shaping and driving the global Atopic Dermatitis therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Atopic Dermatitis therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
– What’s the next big thing in the global Atopic Dermatitis therapeutics market landscape? Identify, understand and capitalize.
For more information, please visit:
http://www.aarkstore.com/reports/Atopic-Dermatitis-Pipeline-Assessment-and-Market-Forecasts-to-2017-65421.html
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether your looking for new product trends or competitive analysis of a new or existing market, Aarkstore Enterprise has the best resource.
Find More Atopic Dermatitis Articles
Atopic Dermatitis – Pipeline Assessment And Market Forecasts To 2017
GlobalData estimated the global atopic dermatitis therapeutics market to be valued at $ 728m in 2009. It is expected to grow to $ 942m at a Compound Annual Growth Rate (CAGR) of 3.3% by 2017. This growth is primarily attributed to an increase in competition among existing products and the presence of a strong pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $ 415m in 2009. However, with most of the demand expected to come from developed economies, the center of global atopic dermatitis therapeutics market activity is potentially due for a paradigm shift.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atopic-Dermatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
In 2009, there were approximately 35 million cases of atopic dermatitis reported within the seven geographies (the US, the UK, Germany, France, Spain, Italy and Japan). This equated to a prevalence of approximately 5%. GlobalData estimates that the number of atopic dermatitis patients is forecast to increase to about 42 million by 2017, representing an increase in prevalence. Some of the factors associated with an increased risk of atopic dermatitis include small family size, higher socioeconomic and educational levels regardless of ethnicity, movement from a rural to an urban environment, and an increased use of antibiotics. Research has indicated that there is a predominance of type-2 helper T cells (Th2) in atopic dermatitis. A higher number of cases would involve the increased uptake of therapeutics, thereby increasing the growth of the market.
The global atopic dermatitis market is heavily fragmented, with numerous generic products at relatively low prices. The patent expiry of marketed products such as Protopic and Elidel in the period 2012 2015 would allow the further entry of generic products at cheaper prices, reducing market growth as well as the market size.
GlobalData, the industry analysis specialist, has released its new report, Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Atopic Dermatitis therapeutics market. The report identifies the key trends shaping and driving the global Atopic Dermatitis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Atopic Dermatitis sector.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atopic-Dermatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries
Related Atopic Dermatitis Articles
talkhealth: Winners of BHBIA 2017 BOBI award!
Winners of Excellence in Data Collection
Last week talkhealth had the honour of winning one of the BHBIA’s (British Healthcare Business Intelligence Association) 2017 BOBI awards. The BOBI Awards (Best of Business Intelligence) are the first and only healthcare-specific business intelligence awards scheme in the UK, giving professionals in our industry an opportunity to gain peer recognition for excellence in business intelligence, market research (including fieldwork) and sales research/analytics. talkhealth were the winners of the Excellence in Data Collection and Fieldwork award sponsored by SERMO. You can see the coverage of the night and read more about the other winners o the BHBIA website.
Award sponsored by SERMO and presented by Eva Laparra
We would like to extend our thanks to the BHBIA and the Judging Panel for selecting us as one of the2017 winners. We would also like to thank you, our members, for your support over the years. We will continue to offer trusted information and support to help you better manage your health, and very much appreciate your help with our surveys and research, all of which enables us to provide you with exactly what you need.
Looking Forward to 2017
With eczema and food allergies
Well that was an interesting year, wasn’t it? Like many of you we’re glad to be through it mostly, and looking forward to a happy and healthy 2017.
However, there has been some good news this last year for families affected by eczema and food allergies, so I thought it would be nice to do a quick round-up of the big ones, in the interests of celebration and optimism.
Eczema treatments
In the field of eczema, we have some exciting new treatments in the pipeline, that we hope might become available and be good for some of us over the coming years; along with some very interesting research projects:
- A new treatment for atopic dermatitis; Eucrisa (crisaborole), was approved in the US: https://nationaleczema.org/people-with-atopic-dermatitis-have-a-new-treatment-option/
- Positive results for the Phase 3 clinical trial of the new biologic drug, dupilumab were reported when used in conjunction with a topical corticosteroid: https://nationaleczema.org/another-step-closer/
Research
- Looking at preventing eczema in babies: https://nationaleczema.org/can-eczema-be-prevented-ask-dr-eric-simpson/
- Considering if there is an association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults: https://www.ncbi.nlm.nih.gov/pubmed/27105659
Scarring
And for anyone with severe scarring, this looks amazing. Perhaps it’s not something that will ever be used in our arena, but the development itself, in which someone’s own skin’s stem cells are used to rebuild skin fills me with hope.
Food allergies
And on the food allergies side, we have new research too:
- On infant feeding and peanuts: http://www.nejm.org/doi/full/10.1056/NEJMoa1414850
- An on a new immunotherapy technique which may help people with food allergies: https://www.sciencedaily.com/releases/2016/10/161026133229.htm
It feels like an exciting time with real breakthroughs being made in both the field of eczema treatment and in the food allergy arena, and we’re hoping 2017 is as fruitful.
As ever, we hope to be picking up on the big stories throughout the coming year and keeping you up to date with all the new changes in research and development on eczema and food allergies. Please do share your stories and experiences with us too.
In the meantime, I hope you have a happy and scratch-free 2017.
WellChild Awards 2017: Nominations open for inspirational children, young people and carers
More than 100,000 children and young people are living with serious illness or exceptional health needs across the UK. Many spend months, even years in hospital simply because there is no support enabling them to leave.
Do you know a seriously ill child or young person who is defying the odds? Or a health professional that goes above and beyond for the children in their care? This is your chance to recognise their achievements and give them a night they will never forget.
National children’s charity, WellChild has opened nominations for the 2017 WellChild Awards, in association with GSK. This prestigious annual event, regularly attended by WellChild Patron Prince Harry celebrates the inspirational qualities of the UK’s seriously ill children and young people and the dedication of those who go that extra mile to make a real difference to their lives – from doctors and nurses, to brothers, sisters and friends.
At last year’s star-studded ceremony at the Dorchester in London, each winner had the chance to chat with Prince Harry and mingle with a room full of their favourite celebrities including Sir Rod Stewart, Gaby Roslin, Ashley Banjo and Perri Kiely from Diversity, TV presenter Katie Piper and Olympic gold medal winner Sam Quek.
So if you know someone who deserves special recognition then nominate them for a WellChild Award by visiting www.wellchild.org.uk/wellchild-awards-2017/ or contacting the charity on 01242 530007 to request a nomination form.
The closing date for all entries is Monday, 1st May 2017.
Anaphylaxis Campaign – Orange Wig Day Friday 19 May 2017
Living with severe allergies and being at risk of anaphylaxis (a severe and potentially fatal allergic reaction) seriously affects the lives of those at risk. There is currently no cure or treatment to prevent anaphylaxis – instead people must learn to manage their condition and carry adrenaline.
The Anaphylaxis Campaign is the only UK wide charity focused on supporting those at risk of severe allergies. We have been providing information and support to patients and their families for over 21 years.
They do not receive any government funding or grants and rely on support from people like you to create a safer and better life for those living with the fear of anaphylactic shock.
So, get ready to show your support to those living with severe allergies by donning your orange wig on Friday 19 May 2017 for Orange Wig Day
To sign up to fundraise for Orange Wig Day as an individual, school or business or to order your orange wig see the Anaphylaxis Campaign website here.